The Fund aims to achieve long term capital growth primarily through investment in a portfolio of equities issued by continental European companies and in derivatives, the underlying assets of which are equities issued by continental European companies.
Name | % Net Assets |
---|---|
Novartis | 5.5% |
Sanofi-Synthelabo | 4.9% |
Total SA | 4.1% |
Bayer | 3.3% |
Anheuser-Busch Inbev | 3.2% |
SAP | 2.7% |
Novo Nordisk A/S | 2.7% |
Unilever NV | 2.6% |
Teleperformance SA | 2.6% |
ING Groep N.V. | 2.4% |
Key | % Net Assets |
---|---|
Novartis | 5.5% |
Sanofi-Synthelabo | 4.9% |
Total SA | 4.1% |
Bayer | 3.3% |
Other | 82.2% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 24/09/1986 |
---|---|
Fund Manager | n/a |
TER | - |
Minimum Investment | |
---|---|
Initial | 1000000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | n/a |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research